Valdes Laboratories
Valdes Laboratories
Valdes Lab - Introduction
Valdes Lab - Awards
Valdes Lab - Publications
Valdes Lab - Personnel

2007 (Publications)

  1. Franke DDH, Jortani SA. Importance of using gas chromatography for diagnosis of patients poisoned with multiple alcohols. Clinica Chemica Acta 2007; Available Online.
  2. Levinson SS. Comparison of apolipoprotein B and non-high density lipoprotein cholesterol for identifying coronary artery disease based on receiver operator curve analysis. Am J Clin Pathol, 2007; 127:449-55.
  3. Proposed Guideline. Immunoassay interference by endogenous antibodies. Subcommittee Member. CLSI and IFCC. I/LA30-P IBS 1-56238-633-6 ISSN 0273-3099. V27: #9
  4. Pugia MJ, Jortani SA, Basu M, Sommer R, Kuo HH, Murphy S, Williamson D, Vranish J, Boyle PJ, Budzinski D, Valdes R Jr, Basu SC. Immunological evaluation of urinary trypsin inhibitors in blood and urine: Role of N- & O-linked glycoproteins. Glycoconj J. 2007;24:5-15.
  5. Thomas A., Tourassi GD, Elmaghraby AS, Valdes Jr R, Jortani SA. Data Mining In Proteomic Mass Spectrometry. Clin Proteomics 2007;2:13-22.
  6. Ihenetu K, Qazzaz HM, Crespo F, Fernandez-Botran R, Valdes, R Jr. Digoxin-Like Immunoreactive Factors Induce Apoptosis in Human Acute T-Cell Lymphoblastic Leukemia. Clin Chem 53:7, 1315-1322 (2007)

2007 (Abstracts)

  1. Franke DDH, Pugia MJ, Valdes RJr, Jortani SA. Characterizing antibody cross-reactivity of adiponectin receptor fragments in human plasma by immuno-mass spectrometry. Accepted for AACC Annual Meeting, San Diego, CA July 2007.
  2. Franke DDH, Valdes RJr, Jortani SA. A method for profiling cross-reactivities of cardiac troponin I antibodies used in current diagnostic assays. Accepted for AACC Annual Meeting, San Diego, CA July 2007.
  3. Steele PS, Jortani SA, Franke DDH, Valdes RJR, Linder MW. Analysis of nucleic acid-protein interactions using competitive binding and mass spectrometry. Accepted for AACC Annual Meeting, San Diego, CA July 2007.

2006 (Publications)

  1. Abudu N, Miller JJ, Levinson SS. Fibrinogen is a co-antioxidant that supplements the vitamin E analog trolox in a model system. Free Radical Research 40:321-31, 2006.
  2. Bashir I, Ihenetu K, Miller JJ, Gim M-H, Lippmann S. A positive pregnancy test in the post-menopausal psychiatric patient – What to think? Psychiatry 3:58-60, 2006.
  3. Franke D., Brown G., Jortani SA. Laboratory Evaluation of A Patient Poisoned With Multiple Alcohols: Potential Pitfall Of Using Enzymatic Assays For Ethanol. J Clin Lig Assay 2006, in press.
  4. Hortin GL, Jortani SA, Ritchie Jr. JC, Valdes Jr. RV, Chan DW. Proteomics: A New Diagnostic Frontier. Clin Chem 2006; 52: 7.
  5. Ihenetu K, Levinson S, Huang A, Miller JJ. HIV Lipodystrophy Syndrome: A case and review. J Clin Ligand Assay 29:32-6, 2006.
  6. Jortani SA, Franke DD, Hernberger M, Valdes Jr. R, Linder MW. Differential expression of transcriptional regulatory proteins is associated with acquired tolerance to acetaminophen induced toxicity. Clin Chem 2006;52:A62-3.
  7. Levinson SS. High Density Lipoprotein Metabolism and Reverse Cholesterol Transport. Invited review. J Clin Ligand Assay 2006;29:32-36.
  8. Levinson SS. Inflammatory and long term risk markers. Clinics of North America, Clinics in Lab Med. Clin Lab Med 2006;26:553-70..
  9. Miller JJ. Post-analytical Data Review. In: Ward-Cook KM, et al., eds. Clinical Diagnostic Technology: The Total Testing Process, Volume 3: The Post-Analytical Phase. Washington, D. C.: AACC Press, 2006; 37-53.
  10. Mukhopadhyay S, Jortani SA, Valdes Jr R, Simmons CQ, Sullivan ED, Miller RD, Summersgill JD. Protein Expression of Analysis Chlamydia pneumoniae Persistence by Combined SELDI TOF-MS and 2D PAGE. Clinical Proteomics 2006.
  11. Shah ZA, Jortani SA, Tauman R, Valdes R Jr, Gozal D. Serum proteomic patterns associated with sleep-disordered breathing in children. Pediatr Res. 2006 Mar;59(3):466-70).
  12. Zhu Y, Valdes R Jr, Simmons CQ, Linder MW, Pugia MJ, Jortani SA. Analysis of ligand binding by bioaffinity mass spectrometry. Clinica Chemica Acta 2006:371(1-2):71-8.
  13. Zhu Y, Hein, DW, Doll MA, Reynolds KK, Abudu N, Valdes R Jr, Linder MW. Simultaneous determination of 7 N-acetyltransferase-2 single-nucleotide variations by allele-specific primer extension assay. Clin Chem 52(6):1033-1039, 2006
  14. Zhu Y, Elin, RJ. Identification of a spurious band on serum protein electrophoresis induced by ethanol treatment. Clin Chim Acta. 366(1-2):341-343, 2006

2006 (Abstracts)

  1. Abudu, N, Miller JJ, Elin RJ. The Effect of Thiocyanate on the Nova Ion-selective Electrode for Magnesium. Clin Chem 52(6):A105, 2006.
  2. Grant SN, Womack Jr., EP, Prabhu PD, Valdes Jr., Jortani SA. Urocortin III in Cardiovascular Disease. Research Louisville, October, 2006.
  3. Makkar A, Banchs J, Hauck MA, Siddiqui TS, Jortani SA, Valdes Jr. R, Koenig SC, Mitchell ME, Tomita-Mitchell A, Prabhu SD. Identification of Genetic Variants of the Tumor Necrosis Factor Receptor 2 Gene (TNFRSF1B) in Patients with Heart Failure. American Heart Association* Scientific Sessions, 2006.

2005 (Publications)

  1. Levinson SS, Elin RJ. Rold of hs-CRP measurements in the current cardiovascular risk assessment. Clin Chim Acta 356:225-226, 2005
  2. Levinson SS, Elin RJ. Response to: Garcia-Moss X, Ordonez-Lianos J. Role of hs-CRP measurements in the current cardiovascular srisk assesment. Clin Chim Acta 2005;356:225-6
  3. Levinson SS. Brief Review and Critical Examination of the Use of hs-CRP for Cardiac Risk Assessment with the conclusion it is Premature to Use this Test. Clin Chim Acta 2005;356:1-8
  4. Levinson SS. Monoclonal free light chains (Bence Jones proteins) in urine. Journal of Clinical Ligand Assay. 27:234-245, 2005
  5. Miller JJ, Levinson SS, Elin RJ. Interferences in Laboratory Tests. Chapter 3, pg 37-76. In:Ward-Cook KM, Kory M. Ward-Cook, Craig A. Lehmann, Larry E. Schoeff, Robert H. Williams, eds. Clinical Diagnostic Technology: The Total Testing Process, Volume 2: The Analytical Phase. Washington, D.C.: AACC Press 2005
  6. Miller JJ. Specimen Collection, Handling, Preparation, and Storage. In: Ward-Cook KM, et al., eds. Clinical Diagnostic Technology: The Total Testing Process, Volume 1: The Preanalytical Phase. Washington, D.C.: AACC Press 2005
  7. Slone SP, Ahmed Z, Cole LA, Elin RJ, Martin AW, Herzig RH, Herzig GP, Miller JJ. Positive pregnancy tests in a non-gravid, pre-menopausal female due to hCG beta chain production by multiple myeloma. Amer J Clin Pathol 124:108-12, 2005.

2005 (Abstracts)

  1. Bon Homme, M, Talwalkar, SS, Miller, JJ, Elin, RJ. Assessment of IMA and BNP to evaluated myocardial ischemia/stress. Clin Chem. 51(6):A26-A27, 2005.
  2. Ihenetu, KU, Abudu, N, Miller, J, Elin RJ. Free light chain assay show greater clinical sensitivity than electrophoresis for detecting plasma cell dyscrasias. Clin Chem. 51(6):A98-A99, 2005.
  3. Talwalkar S, Bon Homme, M, Miller, JJ, Elin, RJ. Relationship between Troponin T and Ischemia Modified Albumin in patients with chest pain. Clin Chem. 51(6):A27, 2005.

2004 (Publications)

  1. Abudu N, Miller JJ, Attaelmannan M and Levinson SS. Co-antioxidants and Vitamins in Arteriosclerosis. Clin Chim Acta 2004; 339:11-25
  2. Abudu N, Miller JJ, Attaelmannan M, Levinson SS. Vitamins in human arteriosclerosis with emphasis on vitamin C. Clin Chim Acta 339:11-25, 2004.
  3. Abudu N, Miller JJ, Levinson SS. Lipoprotein oxidation products and arteriosclerosis: Theory and methods with applicability to the clinical chemistry laboratory. Adv Clin Chem 38:1-35, 2004.
  4. Abudu N, Miller JJ, and Levinson SS. Lipoprotein Oxidation and Arteriosclerosis: Theroy and Method: Applicability for the Chemistry Laboratory. Advances in Clinical Chemistry 2004; 38: 1-35, Ed: Greg S. Makowski, Elsevier.
  5. Bukaveckas BL, Valdes RJr., Linder MW. Pharmacogenetics as Related to the Practice of Cardiothoracic and Vascular Anesthesia. Journal of Cardio and Vasc Anesth 2004; (18)3, 353-365.
  6. Chaturvedi K, Jortani SA. Consequences of adverse drug events/reactions in health care. Louisville Medicine 2004; 51:473-478
  7. El-Mallakh RS, Linder M, Valdes RJr., Looney S. Dialysis of saliva improves accuracy of Saliva lithium determinations. Bipolar Disorders 2004;6:87-89.
  8. Elbeiik T, Surtihadi J, et al, Jortani SA, et al, Valdes RJr, et al. Multicenter Evaluation of the Performance Characteristics of the Bayer VERSANT HCE RNA 3.0 Assay (bDNA). Journal of Clinical Microbiology 2004; 42(2):563-569.
  9. Elin RJ, Levinson SS. Protein Electrophoresis: simple removal of fibrinogen from contaminated serum specimens. LabMedica International 2004;21:8-10
  10. JM Hamlyn. Biosynthesis and Endogenous Cardiac Glycosides by Mammalian Adrenocortical Cells: Three steps Forward. Clin. Chem. 2004; 50 (3)612-620.
  11. Jortani SA, Prabhu SD, Valdes RJr. Strageties for Developing Biomarkers of Heart Failure. Clinical Chemistry 2004; 50(2):265-278.
  12. Jortani SA, Pugia MJ, Elin RJ, Thomas M, Womack EP, Cast T, Valdes R Jr. Sensitive Noninvasive Marker for the Diagnosis of Porbable Bacterial or Viral Infection. Journal of Clinical Lab Analysis 2004; 18:289-295
  13. Jortani, SA, Pradbu S, Valdes R Jr. Development of biomarkers in congestive heart failure. Clinical Chemistry. (Invited Review) 2004; 50; 265-278
  14. Levinson SS, Elin RJ, Miller JJ. Poor predictive value of hs-C reactive protein denotes need for reassessment. Clin Chem 2004; 50:1733-5
  15. Levinson SS, Elin RJ. Response to letter "Serum protein electrophoresis:reptilase treatment is superior to ehtanol precipitation for specific removal of fibrinogen from heparinized plasma samples". Clin Chem 2004;50:1101.
  16. Levinson SS. Antioxidants and antioxidants as prooxidants in Human Arteriosclerosis. J Clin Ligand Assay 2004;27:143-157
  17. Levinson SS. Monoclonal free light chains (Bence Jones proteins) in urine. Invited Review for J Clin Ligand Assay 2004/2005;27:234-45
  18. Levinson SS. Antioxidants can reduce and facilitate lipoprotein oxidation in human arteriosclerosis. Journal of Clinical Ligand Assay. 27:143-157, 2004
  19. Liu L, Miller JJ, Elin RJ. High sensitivity C-reactive protein and cardiovascular disease. Louisville Med 2004;51:393-397.
  20. Pugia MJ, Sommer R, Corey P, Anderson L, Gleason S, Jortani SA, Elin RJ, Gopual DL, Valdes RJr. Lott JA. The uristatin dipstick is useful in distinguishing upper respiratory from urinary Tract infections. Clin Chim Acta 2004; 341:73-81.
  21. Qazzaz HMAM, Cao ZT, Bolanowski DD, Clark BJ, Valdes RJr. De Novo Biosynthesis and Radiolabeling of Mammalian Digitalis-Like Factors. Clin Chem 2004; (50)3:612-620.
  22. Zhang SX, Miller JJ, Gozal D, Wang Y. Whole-body hypoxic preconditioning protects mice against lethal hypoxia by improving lung function. J Appl Physiol. 96:392-7, 2004.

2004 (Abstracts)

  1. Abudu, N, Miller, JJ, Levinson, SS. Synergistic elimination of the pro oxidant effect of vitamin E by fibrinogen. Clin Chem. 50:A186, 2004.
  2. Ahmed, ZA, Elin, RJ, Miller, JJ. Secretion of chorionic gonadotropin by plasma cells in a case of refractory multiple myeloma. Clin Chem. 50:A77 A78, 2004.
  3. Bon Homme, M, Talwalkar, SS, Miller, JJ, Elin, RJ. Assessment of IMA and BNP to evaluated myocardial ischemia/stress. J Clin Ligand Assay. 27(4):288, 2004/2005.
  4. Ihenetu, K, Abudu, N, Elin, RJ, Miller, J. The quality performance of free light chain assays (?/? ratio) in detecting plasma cell dyscrasias. J Clin Ligand Assay. 27(4):287, 2004/2005.
  5. Ihenetu, K, Bashir, I, Singh, H, Keenan, M, Vaish, S, Lippmann, S, Miller, J. Evaluation of positive pregnancy tests on peri-menopausal women in the emergency setting. J Clin Ligand Assay. 27(4):287, 2004/2005.
  6. Talwalkar SS, Bon Homme, M, Miller, JJ, Elin, RJ. Relationship between Troponin T and Ischemia Modified Albumin in patients with chest pain. J Clin Ligand Assay. 27(4):286, 2004/2005.

2003 (Publications)

  1. Barreuto F Jr, Jortani SA, Valdes R Jr, Hoffman RS, Nelson LS. Cardioactive steroid poisoning from an herbal cleansing preparation. Annals of Emergency Medicine 2003; 41(3):396-399
  2. Jortani, SA Immunoassays in clinical and forensic toxicology. J Clin Ligand Assay. 26:3-5, 2003.
  3. Keeling KL, Linder MW, Bukaveckas BL, Jortani SA, Valdes, RJr. A rigorous approach for investigation of unexpected phenytoin toxicity. Journal of Clin Ligand Immunoassay 2003;26(1):19-24
  4. Levinson SS, Miller JJ. Letter to the editor. Response to Dr. Lewis (re: false positive result). Clin Chim Acta 332:143-4, 2003.
  5. Miller JJ, Specimen Collection, Handling, Preparation, and Storage. In: Ward-Cook KM, et al., eds. Clinical Diagnostic Technology: The Total Testing Process, Volume 1: The Preanalytical Phase. Washington, D. C.: AACC Press, 2003;65-90.
  6. Qiu L, Levinson SS, Keeling KL, Elin RJ Convenient and effective method for removing fibrinogen from serum specimens before protein electrophoresis. Clinical Chemistry. 49:868-872, 2003
  7. Valdes R Jr, Linder MW, Jortani SA. What is next in pharmacogenomics? Translating it to clinical practice. Pharmacogenomics 2003;4(4):499-505.

2003 (Abstracts)

  1. Abudu N, Levinson S, Miller J. Triglyceride/HDL cholesterol levels vs. apo-A1 and apo B in coronary artery disease (CAD) for recognition of familial combined hyperlipidemia (FCH). Clin Chem 49:A166, 2003.
  2. Abudu, N, Ahmed, ZA, Hiemer, MF, Miller, JJ. Utility of serum free light chain measurements for clarifying confusing serum protein electrophoresis patterns. CLAS National Meeting, 2004, Chicago. J Clin Ligand Assay. 26:215, 2003.
  3. Abudu, N, Miller, JJ, Levinson, SS. Fibrinogen can eliminate the pro-oxidant effect of vitamin E. CLAS National Meeting, 2004, Chicago. J Clin Ligand Assay. 26:217, 2003.
  4. Ahmed, ZA, Elin, R J, Miller, JJ. Increased chorionic gonadotropin in a multiple myeloma patient: Is it due to interference from the paraprotein? CLAS National Meeting, 2004, Chicago. J Clin Ligand Assay. 26:212, 2003.
  5. Bukaveckas BL, Kahn D, Valdes RJr., Linder MW. Stragety to determine basis for Warfarin resistance. Clin Chem 2003; 49 (suppl): A-120 (Abstract E-11).
  6. Keeling KL, Jortani SA, Womack EP, Valdes R Jr. Measurement of Endogenous Dihydroouabain-like Factor (Dh-OLF) in Heart Failure. Research Louisville 2003
  7. Qazzaz HMH, Lane AN, Valdes RJr. Structural identification of digoxin-like immuno- reactive factors (DLIFs) using NMR spectroscopy. Clin Chem 2003;49 (suppl):A130 (Abstract E-45)
  8. Zhang SX, Wang J, Miller JJ, Mwasaru EF, Gozal D, Wang Y. Whole-body hypoxic preconditioning (WBHPC) protects mice against acute hypoxia by improving organ function in the lung. FASEB J 17(5):A1281, 2003.
  9. Zhu, Y, Miller, JJ. Protein G-Sepharose is superior to polyethylene glycol for the detection of macroprolactin. CLAS National Meeting, 2004, Chicago. J Clin Ligand Assay. 26:213, 2003.

2002 (Publications)

  1. El-Masri MA, Clark BJ, Qazzaz HM, Valdes R Jr. Human Adrenal Cells in Culture Produce Both Ouabain-like and Dihydroouabain-like Factors. Clin Chem 2002;48-10:1720-1730.
  2. Jortani SA, Snyder JW, Valdes R.Jr. Role of clinical laboratory in dealing with Bioterrorism. Journal of the Isfahan Medical Council 2002; 12:32-38. (Translation of above, CCJ)
  3. Levinson SS High density-andbeta-lipoprotein screening for risk of coronary artery disease in the contest of new findings on reverse cholesterol transport. Annals of Clin & Lab Science 32, 123-136, 2002.
  4. Levinson SS, Elin RJ What is CRP telling us about coronary artery disease? Arch Intern Med 162:389-392, 2002.
  5. Levinson SS, Miller JJ. Towards a better understanding of heterophile (and the like) antibody interference with modern immunoassays. Clin Chim Acta 325:1-15, 2002.
  6. Levinson, SS, Elin RJ, Yam L Light chain proteinuria and lysozymuria in a patient with acute monocytic leukemia. Clin Chem 48, 1131-1132, 2002.
  7. Linder MW, Looney S, Adams JE, Johnson N, Antonino-Green D, Lacefield N, Bukaveckas BL, Valdes R.Jr. Warfarin Dose Adjustments Based on CYP2C9 Genetic Polymorphisms. Journal of Thrombosis and Thrombolysis 2002;14(3):227-232.
  8. Valdes R Jr, Jortani SA Unexpected Suppresion of Immunoassay Results by Cross-reactivity: Now a Demonstrated Cause for Concern Clin Chem 43, 405-406, 2002.

2002 (Abstracts)

  1. Abudu N, Tongate C, Miller JJ. Comparison of B-type natriuretic peptide and the N-terminal fragment of its prohormone for assessing congestive heart failure. CLAS National Meeting, 2003, Philadelphia. J Clin Ligand Assay 25(4):366, 2002.
  2. Ahmed ZA, Qiu L, Miller JJ. Is postmenopausal chorionic gonadotropin immunoreactivity due to crossreactivity with luteinizing hormone? CLAS National Meeting, 2003, Philadelphia. J Clin Ligand Assay 25(4):366, 2002.
  3. Bukaveckas BL, Linder MW, Valdes JrR. Detection of CYP2C9*2 allele: comparison of denaturing HPLC (dHPLC) with restriction fragment length polymorphism (RFLP). Clin Chem 2002;48(11):2088
  4. Keeling KL, Jortani SA, Linder MW. Valdes RJr. Prolonged elimination half-life of phenotoin in an elderly patient also on celecoxib. Clin Chem 2002;48(6):A52 Supp.
  5. Keeling KL, Miller JJ. Optimization of total calcium adjusted for albumin binding. CLAS National Meeting, 2003, Philadelphia. J Clin Ligand Assay 25(4):368, 2002.
  6. Keeling KL, Richardson A, Miller JJ. Prealbumin as a marker of nutritional risk improves with length of hospital stay. CLAS National Meeting, 2002, Houston. J Clin Ligand Assay 25(2): 2002.
  7. Linder MW, Johnson N, Valdes RJr. Design of genotyping methods based on pyro- phosphorolysis for pharmacogenetics. Clin Chem 2002;48(6):A49 Supp.
  8. Qazzaz HAM, Clemmens JM, Clark BJ, Valdes JrR. Production of 14C-labeled mammalian ouabain-like factors (OLF) using mouse adrenal Y-1 cells. J Clin Ligand Assay 2002
  9. Qazzaz HMAM, Clements JM, Clark BJ, Valdes RJr. Mevastatin, a cholesterol-lowering drug, inhibits the production of mammalian cardenolides (MC) by mouse adrenalcortical (Y-!) Cells. Abstract P1-510, Endocrine Society's 84th Annual Meeting, San Francisco (June 19-22, 2002).
  10. Qazzaz HMH, Clements JM, El-Masri AM, Valdes RJr. Relative potencies of the Mammalian cardenolides (MC) and their plant counterparts (PC). Clin Chem 2002;48(6): A132 Supp.
  11. Valdes RJr. Molecular basis linking pharmacology to medical genetics. Bioquimia 2002;27 (suppl):77 (abstract S-19); cited in Current Advances in Clinical Chemistry
  12. Valdes RJr., Jortani SA, Elin RJ, Thomas M, Womack EP, Pugia M. Point-of-Care Urinary Trypsin Inhibitor Assay (Uristatin) as an Aid in Diagnosis of Bacterial Infection. Clin Chem Lab Med 2002;40 (suppl):S-295 (Abstract W-RE-003)

2001 (Publications)

  1. Jortani SA, Valdes R.Jr. Mammalian Cardenolides as Biomarkers in Congestive Heart Failure. Cardiovascular Toxicology 2001;1:165-170.
  2. Linder MW, Valdes R.Jr. Genetic Mechanisms for Variability in Drug Response and Toxicity. Journal of Analytical Toxicology 2001;25:405-413.
  3. Linder, MW, Valdes R.Jr. Fundamentals of Pharmacogenetics. In: LM Shaw, ed. Contemporary Practices in Clinical Toxicology. Washington DC: AACC Press, 2001:437-453. [Book Chapter]
  4. Schurr A, Payne RS, Miller JJ, Tseng MT, Rigor BM. Blockade of lactate transport exacerbates delayed neuronal damage in a rat model of cerebral ischemia. Brain Research. 895(1-2):268-72, 2001.
  5. Schurr A, Payne RS, Miller JJ, Tseng MT. Preischemic hyperglycemia-aggravated damage: evidence that lactate utilization is beneficial and glucose-induced corticosterone release is detrimental. J Neurosci Res 66(5):782-9, 2001.
  6. Valdes R Jr., Jortani SA. The Current Assessment of Qualitative and Quantitative Point-of-care Testing of Cardiac Markers. In: Adams, Apple, Jaffe, Wu (eds). Markers in Cardiology: Current and Future Clinical Applications: Futura Publishing Company, 2001:35-46. [Book Chapter]

2001 (Abstracts)

  1. Antonino-Green DM, Linder MW, Lio OL, Looney SW, Fortwengler PF, Valdes R Jr. Ecogenetics of vinyl chloride-induced cancer is linked to a gamma-interferon Dependent activation sequence in the cytochrome P4502E1 gene. Clin Chem 2001; 47(6):A207
  2. Linder MW, Antonino-Green DM, Nota F, Johnson NA, Adams JE, Lacefield N, Valdes R Jr. Predictive value of CYP2C9 genotyping for identification of subjects requiring low Warfarin maintenance dosages. ClinChem 2001;47(6):A75 Supp.
  3. Qazzaz HMA, Bolanowski D, Falkner K, Valdes R Jr. Cytochrome P450 mediates metabolism of Digoxin and its congeners in mammalian liver microsomes. ClinChem 2001;47(6):A17 Supp.
  4. Qazzaz HMA, Bolanowski D, Valdes R Jr. Synthesis of four structurally-related mammalian cardinolides by adrenal Y1 cells: molar ratios and relative concentrations. Clin Chem 2001;47(6):A17 Supp.
  5. Qazzaz HMA, Valdes R Jr. Structural Polymorphis tissue distribution of the endogenous mammalian cardenolides. Clin Chem 2001;47(6):A207

2000 (Publications)

  1. Cao TZ, Valdes R Jr. Role of Sodium Pump in Disease. In: Guido Zimmer, ed. Membrane Structure in Disease and Drug Therapy: Mercel Dekker, 2000:479-512. [Book Chapter]
  2. Jortani SA, Snyder JW, Valdes R Jr. The Role of the Clinical Laboratory in Managing Chemical and Biological Terrorism. Clin Chem 2000;46:1883-1893.
  3. Linder MW, Bosse GM, Henderson MT, Midkiff G, Valdes R Jr. Detection of cocaine metabolite in serum and urine: frequency and correlation with medical diagnosis. Clin Chim Acta 2000;295:179-185.
  4. Qazzaz HMA, El-Masri MA, Valdes R Jr. Secretion of a Lactone-Hydrogenated Ouabain-Like Effector of Sodium Potassium-Adenosine Triphosphatase Activity by Adrenal Cells. Endocrinology 2000;14:3200-3209.
  5. Rose AM, Qazzaz HM, Zolotarjova N, Mellett BJ, Martin AW, Valdes,R Jr. Sodium Pump Isoforms in Zenotransplantation: Importance of Biochemical Compatibility. Clin Chem 2000;46:234-241.

2000 (Abstracts)

  1. Antonino-Green D, Embry M, Miller JJ. Questionable free thyroxine reference range on the Abbott AxSYM. J. Clin Ligand Assay 23:86, 2000.
  2. Antonino-Green D, Linder MW, Fortwengler P, Looney S, Geoghegan TE, Valdes R Jr. Cytochrome P4502E1 polymorphism and glutathione S-transferase genotypes are linked Vinyl chloride-induced angiosarcoma. Proceedings of the American Association for Cancer Research. 2000;41-437
  3. Antonino-Green DM, Linder MW, Lio OL, Looney SW, Fortwengler PHJr., Valdes R Jr. Ecogenetics of vinyl chloride-induced cancer is linked to a gamma-interferon dependent activation sequence in the cytochroms P4502E1 gene. Clin Chem 2000;46(6):A207 Supp.
  4. Brown GL, Miller JJ. Inaccurate auto-dilution and alternative diluents for troponin I and CKMB on the Abbott AxSYM. Clin Chem 46:A41, 2000.
  5. El-Masri MA, Qazzaz HMA, Clark BK, Valdes R Jr. Cultured Human adrenal cells (H295R-1) secret both OLF and Dihydro-OLF: Differential inhibition and phosphorylation of the Na,K-ATPase. The Endocrine Society 82nd Annual Meeting June 21-24, 2000. #1555, p373
  6. El-Masri MA, Qazzaz HMA, Clark BK, Valdes R Jr. Production of ouabain-like factor (OLF) and its chemically reduced form dihydroouabain-like factor (Dihydro-OLF) by human adrenal Cells. FASEB J. 2000; 14(8): A1536
  7. Jortani SA, Harrison HH, Johnson NA, Subudhi J, Valdes R Jr., Monoclonal gammopathy associated with an anomalous digoxin measurement. Clin Chem 2000;46(6):A38 Supp.
  8. Linder MW, Liu LO, Antonino-Green DM, Valdes R Jr. Suppression of CYP2E1 Promoter Activity by y-Interferon and Loss of Response due to a naturally occurring G-35/T Nucleotide sequence Polymorphism. ClinChem 2000;46(11):1881
  9. Linder MW, Nota F, Valdes R Jr. Differences in CYP2C9 allele frequencies between American Caucasians, African Americans and native Africans. Clin Chem 2000;46(6) A199 Supp.
  10. Miller JJ. Hemoglobin F interference in creatinine assays. Clin Chem 46:A40-1, 2000.
  11. Qazzaz HMA, El-Masri M, Bolanowski DD, Clark BJ, Valdes R Jr. Engodenous synthesis of a dihydro-ouabain-like factor (Dihydro-OLF) by mammalian adrenal Y1 cells. Clin Chem 2000; 46( 6):A197 Supp.
  12. Qazzaz HMA, El-Masri MA, Clark BK, Valdes R Jr. Murine Y1 adrenal cells secrete structurally-related ouabain-like factors (OLF, OLF-genin, and Dihydro-OLF). The Endocrine Society 82nd Annual Meeting June 21-24, 2000. #1556, p373
  13. Qazzaz HMA, El-Masri MA. Valdes R Jr. Tissue concentration of four structurally-related endogenous mammalian cardenolides. FASEB J. 2000; 14(8): A1536
  14. Qazzaz HMA, Valdes R Jr. Four structurally-related endogenous mammalian cardenolides: Relative concentrations in tissues. The Endocrine Society 82nd Annual Meeting June 21-24, 2000. #1557, p273
  15. Qazzaz HMA, Valdes R Jr. Structural polymorphic tissue distribution of the endogenous mammalian cardenolides. Clin Chem 2000;46(6):A127 Supp.
  16. Schurr A, Payne RS, Miller JJ, Shechter Y, Rigor BM. Vanadate abolishes preischemic hyperglycemia-enhanced neuronal damage in vivo. Soc. Neurosci. Abstr. 26:764, 2000.
  17. Shoemaker LR, Miller JJ, Pierce WM, Schurman SJ, Bergstrom WH. Furosemide-induced hypercalciuria: A model of hypercalciuric Bartter Syndrome. Pediatr Res 47:451A, 2000.

1999 (Publications)

  1. Apple FS, Christenson RH, Valdes R Jr. , et al. Simultaneous Rapid Measurement of Whole Blood Myoglobin, Creatine Kinase MB and Cardiac Troponin I by the Triage Cardiac Panel for Detection of Myocardial Infarction. Clin Chem 1999;45:199-205.
  2. Apple FS, Christenson RH, Valdes R Jr., Andriak AJ, Berg A, Duh S-H, Feng Y-J, Jortani SA, Johnson NA, Koplen B, Mascotti K, Wu AHB. Simultaneous Rapid Measurement of Whole Blood Myoglobin, Creatine Kinase MB, and Cardiac Troponin I by the Triage Cardiac Panel for Detection of Myocardial Infarction. Clin Chem 1999;45:2:199-205.
  3. Cao TZ, Bideau R, Valdes R Jr., Elin RJ. Acute hypermagnesemia and respiratory arrest following infusion of MgSO4 for tocolysis. Clinica Chimica Acta 1999;285:191-193.
  4. Cao TZ, Linder MW, Jevans AW, Brown G, Valdes R Jr. Comparison of Tacrolimus Concentrations Measured by the Imx Tacrolimus II vs the PRO-TRAC II FK506 ELISA assays. Clin Chem 1999;45:1868-1870.
  5. Grider G, El-Mallakh RS, Huff MO, Buss TJR, Miller J, Valdes R Jr. Endogenous digoxin-like immunoreactive factor (DLIF) serum concentrations are decreased in manic bi-polar patients compared to normal controls. Journal of Affective Disorders 1999;54:261-267.
  6. Jortani SA, Pinar A, Johnson NA, Valdes R Jr. Validity of unbound digoxin measurements by immunoassays in presence of antidote (Digibind®). Clinica Chimica Acta 1999;283:159-169.
  7. Linder MW, Valdes R Jr. Pharmacogenetics in the Practice of Laboratory Medicine. Molec Diag 1999;4:365-379.
  8. Linder MW, Valdes R Jr. Fundamentals and Applications of Pharmacogenetics for the Clinical Laboratory. Annals of Clin and Lab Sci 1999; 29:140-149.
  9. Miller JJ. Cross-reactivity and methods to detect it. ASCP Tech Sample No. CC-5, 1999.
  10. Qazzaz HMAM, El-Masri MA, Stolowich NJ, Valdes R Jr. Two biologically active isomers of dihydroouabain isolated from commercial preparation. Biochem Bioph Acta 1999;1472:486-497
  11. Schurr A, Payne RS, Miller JJ, Rigor BM: An increase in lactate output by brain tissue serves to meet the energy needs of glutamate-activated neurons. J Neurosci 19:34-9, 1999.
  12. Schurr A, Payne RS, Miller JJ, Rigor BM: Study of cerebral energy metabolism using the rat hippocampal slice preparation. Methods (a companion to Methods in Enzymology) 18:117-26, 1999.
  13. Schurr A, Payne RS, Tseng MT, Miller JJ, Rigor BM. “The Glucose Paradox in Cerebral Ischemia: New Insights.” In Oxidative/Energy Metabolism in Neurodegenerative Disorders, Annals of the New York Academy of Sciences, 893:386-90, 1999.
    14. , Warshaw MM, Valdes R.Jr. National Academy of Clinical Biochemistry standards of laboratory practice: Recommendations for the use of cardiac markers in coronary artery diseases. Clin Chem 1999;45:1104-21.
  14. Valdes R Jr., Jortani SA. Standardizing utilization of biomarkers in diagnosis and management of acute cardiac syndromes. Clin Chim Acta 1999;284:135-140.

1999 (Abstracts)

  1. Cao TZ, Bideau R, Valdes R Jr., Elin RJ. Acute hypermagnesemia and Respiratory Arrest following infusion of MgSO4 for tocolysis. Clin Chem 1999;45(6):A67 Supp
  2. Cao TZ, Qazzaz HMAM, Bolanowski DD, El-Masri MA, Clark BJ, Valdes R Jr. Ex vivo production of digoxin-like immunoreactive factors (DLIF) by mouse adrenal cortex tumor (Y-1) cells. Clin Chem 1999;45(6):A83 Supp.
  3. El-Masri M, Qazzaz HMA, Valdes R Jr. Development of an enzyme immunoassay (EIA) used in the discovery of a dihydro-OLF in mammals. The Endocrine Society Annual Meeting 1999;P2-284:p339.
  4. El-Masri MA, Qazzaz HMAM, Valdes R Jr. Homology of endogenous isomers of mammalian ouabain-like factor (OLF and Dihydro-)LF) isolated from human and bovine tissues. Clin Chem 1999;45(6):A82 Supp.
  5. El-Masri, MA, Qazzaz HMAM, Valdes R Jr. An antiserum for detection of a newly discovered dihydroouabain-like factor (Dihydro-OLF) isolated from mammals. Clin Chem 1999;45(6):A82 Supp.
  6. Jortani SA, Valdes R Jr. Performance of the valproic acid assay on Beckman Coulter’s IMMAGE® immunohistochemistry system. Clin Chem 1999;45(6):A122 Supp.
  7. Linder MW, Nota F, Valdes RM, Looney S, Valdes R Jr. Criteria for establishing the use of pharmacogenetic (PG) analysis for optimizing warfarin therapy. Clin Chem 1999;45(6):A124 Supp.
  8. Linder MW, Valdes R Jr. Pharmacogenetics (PG): Fundamentals and Applications to individualized drug therapy. J Clin Ligand Assay 1999;22:91(Workshop abstract)
  9. Linder MW, Valdes RM, Looney S, Valdes R Jr. An approach for design of pharmacogenetic (PG) screening-profiles and estimating impact on regional drug utilization. Clin Chem 1999;45(6):A125 Supp.
  10. Parker DR, Baum JM, Kilo C, Jortani S, Valdes R Jr., Pinson M, Johnson N, Thompson S. Evaluation of a new amperometric glucose monitoring system, with increased data storage at two clinical sites. Clin Chem Lab Med; 37, Spec Supp, ppS1-S576; June 1999.
  11. Payne RS, Schurr A, Tseng MT, Miller JJ, Rigor BM. Corticosterone: a possible candidate for hyperglycemia-enhanced ischemic neuronal damage. Soc Neurosci Abst 25:1845, 1999.
  12. Qazzaz H, Cao TZ, Bolanowski DD, El-Masri MA, Clark BJ, Valdes R Jr. Incorporation of C- 14 into digoxin-like immunoreactive factors (DLIF) using mouse adrenal Y-1 cells. The Endocrine Society Annual Meeting 1999;P3-478:p541.
  13. Qazzaz HMA, El-Masri M, Valdes R Jr. Differential inhibition of Na,K-ATPase activity by newly discovered isomers of mammalian ouabain-like factors. The Endocrine Society Annual Meeting 1999;P2-283:p340.
  14. Qazzaz HMA, El-Masri M, Valdes R Jr. Discovery of a new mammalian lactone-hydrogenated isomer of OLF. The Endocrine Society Annual Meeting 1999;P2-278:p339.
  15. Qazzaz HMAM, Cao TZ, Bolanowski DD, El-Masri MA, Clark B, Valdes R Jr. Incorporation of C-14 into digoxin-like immunoreactive factor (DLIF) using mouse adrenal Y-1 cells. FASEB J. 1999 13(7):A1471
  16. Qazzaz HMAM, El-Masri MA, Valdes R Jr. A mammalian-derived dihydroouabain-like factor (Dihydro-OLF inhibits na,K-ATPase activity. Clin Chem 1999;45(6):A82 Supp.
  17. Qazzaz HMAM, El-Masri, MA, Valdes R Jr. A newly discovered lactone-hydrogenated isomer (Dihydro-OLF) of mammalian ouabain-like factor (OLF) differentially inhibits the sodium pump. FASEB-J. 1999;13(7):A1470
  18. Schurr A, Payne RS, Miller JJ, Tseng MT, Rigor BM. Aerobic lactate utilization is paramount for the rescue of brain tissue postischemia. J Neurochem 72:S32, 1999.
  19. Schurr A, Payne RS, Miller JJ, Tseng MT, Rigor BM. The dogma of lactic acid-related ischemic damage: refuting evidence and counter hypothesis. Soc Neurosci Abst 25:1845, 1999.
  20. Schurr A, Payne RS, Tseng MT, Miller JJ, Rigor BM. A sweet and sour recipe for neuroprotection against cerebral ischemia. Presented at the Fifth International Brain Research Organization World Congress of Neuroscience, Jerusalem, Israel, July 11-15, 1999.
  21. Schurr A, Payne RS, Tseng MT, Miller JJ, Rigor BM. The Glucose Paradox in Cerebral Ischemia: New Insights. Presented at the New York Acadamy of Sciences meeting, New York, NY, March 22, 1999.

1998 (Publications)

  1. Chan S-A, Reid KH, Schurr A, Miller JJ, Iyer V, Tseng MT: Fosphenytoin reduces hippocampal neuronal damage in rat following transient global ischemia. Acta Neurochir (Wien) 140:175-80, 1998.
  2. Rose AM, Mellett BJ, Valdes R Jr, Kleinman JE, Herman M, Li R, El-Mallakh RS. Alpha 2 isoform of the Na,K-adenosine triphosphatase is reduced in temporal cortex of bi-polar individuals. Biol Psychiatry 1998;44:892-897.
  3. Schurr A, Payne RS, Miller JJ, Rigor BM. "Direct Evidence That Lactate is an Obligatory Aerobic Energy Substrate for Functional Recovery Posthypoxia In Vitro." In Progress in Alzheimer's and Parkinson's Diseases. Fisher A, Yoshida M, Hanin I, Eds., Plenum, New York, pp 171-6, 1998.
  4. Valdes R Jr, Jortani SA, Gheorghiade M. Standards of Laboratory Practice: Cardiac Drug Monitoring. Clin Chem 1998;44:1096-1109.

1998 (Abstracts)

  1. Cao TZ, Jevans A, Brown G, Linder MW, Valdes R Jr. Discrepancies between Tacrolimus concentrations measured using the MEIA and ELISA methods are due to differences in drug recovery. Clin Chem 1998;44(6):A87 Supp.
  2. Cao TZ, Miller JJ, Linder MW, Valdes R Jr. Alkaline phosphatase enhances the conversion of fosphenytoin to phenytoin in vitro. Clin Chem 1998;44(6):A102 Supp.
  3. Cao TZ, Miller JJ, Tongate C, Valdes R Jr. Calibration verification after manufacturer supplied calibration of alphafetoprotein failed to detect degraded reagents. Clin Chem 1998;44(6):A39 Supp.
  4. Chan SA, Tseng MT, Guo ZS, Reid KH, Schurr A, Miller JJ, Iyer VG. Absence of apoptotic cells in rat hippocampus following transient global ischemia. FASEB J. 12:A755, 1998.
  5. Jortani SA, Johnson NA, Brown GL, Valdes R Jr. Decreased recovery of digoxin in serum collected from pregnant women. Clin Chem 1998;44(6):A87 Supp.
  6. Koplen B, Wu AHB, Christenson RH, Valdes R Jr, Jortani SA, Johnson NA, Berg A, Apple FS. Clinical evaluation of the biosite triage cardiac panel for the simultaneous measurement of whole blood cTnI, CK MB and myoglobin for detection of myocardial infarction. Clin Chem 1998;44(6):A116 Supp.
  7. Linder MW, Bosse G, Midkiff G, Henderson M, Valdes R Jr. Serum drug screening reliably predicts acute cocaine intoxication and identifies multiple drugs not detected in urine. Clin Chem 1998;44(6):A88 Supp.
  8. Miller JJ, Brown G, Stone MA. Inaccurate estimation of interference from hemolysis when specimens are prepared by spiking an erythrocyte lysate into serum. Clin Chem 44:A141, 1998.
  9. Rigor BM, Schurr A, Miller JJ, Payne RS. Neurons endure excitation by glutamate via utilization of glia-generated lactate as aerobic fuel. Anesthesiology 89:A760, 1998.
  10. Schurr A, Miller JJ, Payne RS, Rigor BM. Glutamate boosts glial glycolytic lactate output to meet energy demands of excited neurons. Soc Neruosci. Abst 24:1166, 1998.
  11. Schurr A, Miller JJ, Payne RS, Rigor BM. Lactate, generated by glia, is an indispensable neuronal energy substrate upon activation by glutamate. 3rd European Meeting on Glial Cell Function in Health and Disease - Dialogue between Glia and Neurons, Athens, Greece, May 6-10, 1998.
  12. Tseng MT, Chan SA, Guo SZ, Reid KH, Schurr A, Miller JJ, Iyer VG. Transient global ischemia induced ultrastructure changes in adenohypophysis. FASEB J. 12:A747, 1998.
  13. Tseng MT, Chan SA, Reid KH, Schurr A, Miller JJ, Iyer VG. Cardiac arrest induced transient global ischemia, a model for screening neuroprotective compounds. Presented at the 8th Annual Spring Brain Conference in Sedona, AZ, March 1998.

1997 (Publications)

  1. Gupta A, Joshi P, Jortani SA, Valdes R Jr., Thorkelsson T, Verjee Z, Shemie S. A case of nondigitalis cardiac glycoside toxicity. Therap Drug Monitor 1997;19:711-714.
  2. Hobbs GA, Jortani SA, Valdes R Jr. Implementation of a successful on-call system in clinical chemistry. Am J Clin Path 1997;108:556-563.
  3. Jortani SA, Miller JJ, Helm BA, Johnson NA, Valdes R Jr. Suppression of immunoassay results by cross-reactivity. J Clin Lig Assay 1997;20:177-179.
  4. Jortani SA, Trepanier D, Yatscoff R. Valdes R Jr. Convergence of three methods to Resolve discrepant immunoassay digitoxin results. Clin Chem 1997;43:1805-1808.
  5. Jortani SA, Valdes R Jr. Digoxin and its related endogenous factors. Crit Rev Clin Lab Sci. 1997;34:225-274.
  6. Jortani SA, Valdes R Jr. Antiarrhythmics. In: Therapeutic Drug Monitoring and Toxicology. AACC, TDM/TOX, 1997;18 (No. 8):259-275.
  7. Linder MW, Prough RA, Valdes R Jr. Pharmacogenetics: A laboratory tool for optimizing therapeutic efficiency. Clin Chem 1997;43:254-266.
  8. Schurr A, Payne RS, Miller JJ, Rigor BM. Brain lactate, not glucose, fuels the recovery of synaptic function from hypoxia upon reoxygenation: an in vitro study. Brain Res 744:105-111, 1997.
  9. Schurr A, Payne RS, Miller JJ, Rigor BM. Glia are the main source of lactate utilization by neurons for recovery of function posthypoxia. Brain Res 774:221-4, 1997.

1997 (Abstracts)

  1. Cao Z, Stapp D, Linder MW, Miller JJ, Valdes R Jr. Conversion of phosphenytoin to phenytoin in vitro. Clin Chem 1997;43:S219. (Best Poster Award)
  2. Jortani SA, Helm RA, Johnson NA, Valdes R Jr. Suspected polar metabolites of digitoxin account for discrepancy in digitoxin immunoassay results. Clin Chem 1997;43:S212.
  3. Jortani SA, Trepanier D, Valdes R Jr, Yatscoff R. Convergence of three methods to resolve discrepant immunoassay digitoxin results. AACC Oak Ridge Conference poster # 67, April 10, 1997, St. Louis MO.
  4. Linder MW, Midkiff G, Hester ST, Valdes R Jr. False positive bartiburate screen in urine of a neonate administered naloxone, erythromycin and gentamycin. Clin Chem 1997;43:S218.
  5. Payne RS, Miller JJ, Rigor BM, Levy RS, Schurr A: Glia are the source of lactate utilized aerobically by neurons for recovery of function posthypoxia. Soc Neurosci Abst 23:1378, 1997.
  6. Qazzaz HMA El-Masri MA, Helm, Valdes R Jr. A structural and metabolic link between endogenous digitalis- and ouabain-like sodium pump inhibitors. FASEB Journal 1997;11(9):1423.
  7. Qazzaz HMA El-Masri MA, Valdes R Jr. Isolation of two chromatographically and biologically distinct components from a dihydroouabain commercial preparation. FASEB Journal 1997;11(9):1423.
  8. Qazzaz HMA, El-Masri MA, Goudy SL, Valdes R Jr. A commercially available standard for diydroouabain has two chromatographically distinct biologically active components. Clin Chem 1997;43:S191.
  9. Qazzaz HMA, Helm RA, Valdes RM, Mellet BJ, Johnson NA, El-Masri MA, Valdes R Jr. A metabolic and structural link between endogenous cardiac glycoside-like factors. Clin Chem 1997;43:S186.
  10. Reid KH, Schurr A, Tseng MT, Miller JJ, Iyer VG. Cardiac arrest induced susceptibility to sound-triggered seizures in rat: effects of glucose and therapeutic agents. Focus on Epilepsy IV, Le Chantecler, Val David, Que., August 26-29, 1997.
  11. Rigor BM, Schurr A, Payne RS, Miller J. Lactate: A mandatory aerobic fuel for recovery of brain function posthypoxia. Anesthesiology 87 :A709, 1997.
  12. Schurr A, Miller JJ, Payne RS, Rigor BM. Brain anaerobic lactate production: A suicide note or a survival kit? J Neurochem 69:S270B, 1997.
  13. Schurr A, Payne RS, Miller JJ, Rigor BM. Aerobic utilization of anaerobically-accumulated lactate is mandatory for post-hypoxia recovery of neuronal function in vitro. J Cereb Blood Flow Metab 17:S622, 1997.
  14. Schurr A, Payne RS, Miller JJ, Rigor BM. Direct evidence that brain lactate is a mandatory aerobic energy substrate for posthypoxia recovery of function. Soc Neurosci Abst 23:1378, 1997.
  15. Valdes R Jr, Jortani SA, Hobbs GA. Developing and implementing a successful pro-active on -call system in laboratory medicine. Ann Clin Lab Sci 1997;27:315.

1996 (Publications)

  1. Apple FS, Wu AHB, Valdes R Jr. Serum cardiac troponin T concentrations in hospitalized patients without myocardial infarction. Scan J Clin Lab Invest 1996;56:63-68.
  2. Jortani SA, Helm RA, Valdes R Jr. Inhibition of Na,K-ATPase by oleandrin and oleandrigenin and their detection by digoxin immunoassays. Clin Chem 1996:42;1654-1658.
  3. Jortani SA, Miller JJ, Valdes R Jr. Resolving clinically discrepant digoxin results: a case study involving multiple interferences. J Clin Ligand Assay 1996;19:131-137.
  4. Miller JJ, Levinson SS. "Interferences in Immunoassays", in Immunoassays, Diamandis EP, Christopoulos TK (Eds.), Academic Press, San Diego, 1996.
  5. Miller JJ, Straub RW, Valdes R Jr. Analytical performance of a monoclonal digoxin assay with increased specificity on the ACS:180. Therap Drug Monitor 1996;18:65-72.
  6. Qazzaz MAM, Goudy SL, Valdes R Jr. Deglycosylated products of endogenous digoxin-like immunoreactive factor (DLIF) in mammalian tissue. J Biol Chem 1996;271:8731-8737.
  7. Qazzaz MAM, Jortani SA, Poole JM, Valdes, R Jr. Evidence for presence of a reduced form of digoxin-like immunoreactive factor (dihydro-DLIF) in mammalian tissues. Clin Chem 1996;42:1092-1099.
  8. Qazzaz MAM, Valdes R Jr. Simultaneous isolation of endogenous digoxin-like immunoreactive factor, ouabain-like factor, and deglycosylated congeners from mammalian tissue. Arch Biochem Biophys 1996;328:193-200.
  9. Reid KH, Young C, Schurr A, Tseng M, Payne RS, Keelen P, Miller J, Iyer V. Audiogenic seizures following global ischemia induced by chest compression in Long-Evans rats. Epilepsy Res 23:195-209, 1996.

1996 (Abstracts)

  1. Hess P, Miller J. Assessment of laboratory error. J Clinical Ligand Assay 19:87, 1996.
  2. Hobbs GA, Miller JJ. Mannitol interferes with the measurement of phosphorus on the DuPont Dimension but not on three other analyzers. Clin Chem 42:S314, 1996.
  3. Jortani SA, Broadbent J, Miller JJ, Stone MA, Hooker EA, Wagner S Bolli R, Valdes R Jr. Unexplained concentrations of cardiac troponin I in patients ruled out for acute myocardial infarction (AMI). Clin Chem 1996;42:S245.
  4. Jortani SA, Helm R, Valdes R Jr. Two cases in which polar digoxin metabolites explain discrepancyin digoxin immunoassay. Clin Chem 1996;42:S212.
  5. Jortani SA, Miler JJ, Helm R, Valdes R Jr. Unexpected suppression of digoxin values caused by DLIF. Clin Chem 1996;42:S124.
  6. Li MM, Payne RS, Reid KH, Miller JJ, Iyer VG, Tseng MT, Rigor BM, Schurr A. The role of hyperglycemia in cerebral ischemic damage: An in vivo - in vitro study. Soc. Neruosci. Abst 22: 1426, 1996.
  7. Linder MW, Valdes RM, Hendler FJ, Valdes R Jr. CYP2E1 genotype as a biomarker of cancer risk. Clin Chem 1996;42:S262.
  8. Lynch D, Gross M, Knuckles H, O’Morchoe S, Weatherholt J, Weigand R, Chan D, Haven M, Painter P, Schwartz M, Stenzt F, Valdes R Jr. Clinical evaluation comparing AxSYM CA 15-3 and IMx CA 15-3. Clin Chem 1996;42:S263.
  9. Miller JJ, Jortani SA, Broadbent J, Stone MA, Hooker EA, Wagner S Bolli R, Valdes R Jr. Clinical diagnostic performance of cardiac troponin I for acute myocardial infarction. J Clin Ligand Assay 1996;19:89.
  10. Qazzaz HMAM, Valdes R Jr. A modified DLIF-aglycone in human serum inhibits the sodium pump. Clin Chem 1996;42:S230.
  11. Qazzaz HMAM, Valdes R Jr. DLIF-genin is structurally distinct from digoxigenin. Clin Chem 1996;42:S241.
  12. Rose AM, Mellet BJ, Valdes R Jr. Na,K-ATPase isoform(s)in pig heart explains reduced response to cardiac glycosides. Clin Chem 1996;42:S245.
  13. Schurr A, Payne RS, Miller JJ, Rigor BM. Lactate, not glucose, is the energy substrate that fuels recovery of neuronal function after hypoxia in vitro. Soc Neurosci Abst 22:3, 1996.
  14. Zolotarjova N, Miller JJ, Valdes R Jr. Methodological differences in the diagnosis of severe hypophosphatemia. Clin Chem 1996;42:S274.

 

View Publications List

by Lab Divisions

 

 

Valdes Laboratories is based at the

Department of Pathology and Laboratory Medicine, University of Louisville

© 2003 Valdes Laboratories | Designed by Guangming Cui

 

Diagnostic Reference Lab Pharmacogenetics Diagnostic Lab DLIF Research Lab Clin Chem Fellowship University of Louisville